Biotech IV Monitor

PRAX — Praxis Precision Medicines Inc.

$9.1B market cap · 4 upcoming readouts tracked

Clinical trial readout dates for Praxis Precision Medicines Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.

Next readoutDecember 2026in ~1 month
Upcoming readouts44 Phase 3
Market cap$9.1B
Cash & investments$1.84B~20 quarters at last loss rate
Recent 8-K filings2latest 2026-11-12

Upcoming readouts

Phase 3 1mg elsunersen
Epileptic Encephalopathy; SCN2A Encephalopathy · NCT07019922
December 2026
Recruiting
Phase 3 1.0mg/kg/day PRAX-562
Developmental and Epileptic Encephalopathy 1 · NCT07010471
December 2026
Ongoing
Phase 3 40 mg/day vormatrogine for 12 weeks
Focal Epilepsy · NCT07505004
January 2027
Ongoing
Phase 3 vormatrogine
Epilepsy, Tonic-Clonic; Focal Seizure · NCT07287163
May 2028
Enrolling

Cash position

Praxis Precision Medicines Inc. reported $1.84B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-09). Its net loss for that quarter was $94M; at that rate the cash would last about 20 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Other Events — often topline trial data2026-11-12
8-K Results of Operations — earnings, may carry pipeline updates2026-11-09

Companies working on similar indications

Discussion

No messages yet. If you follow PRAX, you can start the conversation.
Track PRAX in real time
See live implied volatility for PRAX and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on PRAX
Contact — questions or corrections about PRAX: dukeupt@gmail.com